Ann: RELINT: FPH: Disclosure of Director & Senior Managers...

• Release Date: 11/12/15 09:43
• Summary: RELINT: FPH: Disclosure of Director & Senior Managers Relevant Interests
• Price Sensitive: No
• Download Document  13.63KB

					FPH
11/12/2015 09:43
RELINT
NOT PRICE SENSITIVE
REL: 0943 HRS Fisher & Paykel Healthcare Corporation Limited

RELINT: FPH: Disclosure of Director & Senior Managers Relevant Interests

To NZX Limited; and
Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  11-Dec-15
Date of last disclosure:   10-Sep-15

Director or senior manager giving disclosure
Full name(s):  Lewis George GRADON
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Senior VP Products & Technology

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  "(a) Beneficial Interest in
Ordinary Shares
(b) Beneficial Interest in Options to acquire Ordinary Shares
"
For that relevant interest-
Number held in class before acquisition or disposal:  "(a) 589,641
(b) 620,000
"
Number held in class after acquisition or disposal:  "(a) 647,205
(b) 500,000
"
Current registered holder(s):  Lewis George GRADON
Registered holder(s) once transfers are registered:  Lewis George GRADON

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Date of transaction:  "(a) 7 December 2015
(b) 8 December 2015
"
Nature of transaction:  "(a) Exercise of 120,000 Options to acquire Ordinary
Shares
(b) Sale of 30,000 Ordinary Shares"
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  "(a)
NZ$753,180
(b) NZ$247,076.65"
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were aquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the aquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:

Nature of relevant interest:  Performance Share Rights over Ordinary Shares
For that relevant interest,-
Number held in class:  83,500
Current registered holder(s):  Lewis George GRADON
For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Cerification
I certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make
this disclosure by all persons for whom it is made.

To NZX Limited; and
Name of listed issuer:  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  11-Dec-15
Date of last disclosure:   10-Nov-15

Director or senior manager giving disclosure
Full name(s):  ANTONY GEORGE BARCLAY
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  "(a) Beneficial interest in
Ordinary Shares
(b) Beneficial interest in options to acquire Ordinary Shares"
For that relevant interest-
Number held in class before acquisition or disposal:  "(a) 92,549
(b) 321,166"
Number held in class after acquisition or disposal:  "(a) 102,549
(b) 279,500"
Current registered holder(s):  ANTONY GEORGE BARCLAY
Registered holder(s) once transfers are registered:  ANTONY GEORGE BARCLAY

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure-
Date of transaction:  "(a) 7 December 2015
(b) 7 December 2015"
Nature of transaction:  "(a) Exercise of 41,666 Options to acquire Ordinary
Shares
(b) Sale of 19,895 Ordinary Shares"
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or recieved for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  "(a)
NZ$257,141.72
(b) NZ$166,616.65"
Number of financial products to which the transaction related:  "(a) 29,895
(b) 19,895"
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were aquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the aquisition or
disposal to proceed during the closed period:  Not Applicable
Date of the prior written clearance (if any):  Not Applicable

Summary of other relevant interests after acquisition or disposal:

Nature of relevant interest:  "(a) Performance Share Rights
(b) Shares in Trust under Employee Share Scheme"
For that relevant interest,-
Number held in class:  "(a) 56,500
(b) 410"
Current registered holder(s):  "(a) ANTONY GEORGE BARCLAY
(b) Fisher & Paykel Healthcare Employee Share Purchase Trustee Limited"

For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Cerification
I certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make
this disclosure by all persons for whom it is made.

To NZX Limited; and
D  Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:  11-Dec-15
Date of last disclosure:   8-Sep-15

Director or senior manager giving disclosure
Full name(s):  Michael Grenfell DANIELL
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):  Not Applicable
Position held in listed issuer:  "Managing Director/
Chief Executive Officer"

Summary of acquisition or disposal of relevant interest (excluding specified
derivatives)
Class of affected quoted financial products:   Ordinary Shares
Nature of the affected relevant interest(s):  "(a) Beneficial Interest in
Ordinary Shares
(b) Beneficial interest in options to acquire Ordinary Shares"
For that relevant interest-
Number held in class before (a) exercise; (b) acquisition:  "(a) 914,879
(b) 830,000 "
Number held in class after (a) exercise; (b) acquistion:  "(a) 972,497
(b)  710,000"
Current registered holder(s):  "(a) Michael Grenfell DANIELL, Daniell Family
Trust
(b) Michael Grenfell DANIELL"
Registered holder(s) once transfers are registered:  "(a) Michael Grenfell
DANIELL, Daniell Family Trust
(b) Michael Grenfell DANIELL"

Summary of acquisition or disposal of specified derivatives relevant interest
(if applicable)
Type of affected derivative:   Not applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: Two
Details of transactions requiring disclosure-
Details of transactions requiring disclosure-
Date of transaction:  "(a) 7 December 2015
(b) 4 December 2015"
Nature of transaction:  "(a) Exercise of 120,000 Options to acquire Ordinary
Shares
(b) Sale of 60,000 Ordinary Shares"
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be
readily by converted into a cash value, describe the consideration:  "(a)
NZ$753,646.69
(b) NZ$505,271.93"
Number of financial products to which the transaction related:
If the issuer has a financial products trading policy that prohibits
directors or senior managers from trading during any period without written
clearance (a closed period) include the following details--
Whether relevant interests were acquired or disposed of during a closed
period:  No
Whether prior written clearance was provided to allow the acquisition or
disposal to proceed during the closed period:  Not applicable
Date of the prior written clearance (if any):  Not applicable

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Nature of relevant interest:  Performance Share Rights over Ordinary Shares
For that relevant interest,-
Number held in class:  110,000
Current registered holder(s):  MICHAEL GRENFELL DANIELL

For a derivative relevant interest,-
Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of
underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically
settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration
payable under the derivative or the value of the derivative is affected by
the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the
nature of the relevant interest in the derivative:

Certification
I certify that, to the best of my knowledge and belief, the information
contained in this disclosure is correct and that I am duly authorised to make
this disclosure by all persons for whom it is made.
End CA:00274988 For:FPH    Type:RELINT     Time:2015-12-11 09:43:37